Data edition of
Residue An evidence-graded reference for peptide science

Retatrutide dosage in clinical trials

What dose levels researchers actually tested, quoted from the trial registry and the published reports — so the numbers circulating online can be checked against their source.

Doses in published trials

Table 1. Dose arms of the principal published Retatrutide trials, as reported in the cited paper.
TrialPopulationDose armsScheduleRef.
Phase 2 obesity (NCT04881760)Adults with obesity or overweight plus a condition; n=3381, 4, 8, 12 mg (4 and 8 mg with 2 mg or 4 mg start)Once weekly SC, 48 weeks1
Phase 2 type 2 diabetes (NCT04867785)Adults with type 2 diabetes; n=2810.5, 4, 8, 12 mg; comparator dulaglutide 1.5 mgOnce weekly SC, 36 weeks2
TRIUMPH-1 (NCT05929066)Adults with obesity, no diabetes; n=2,3394, 9, 12 mgOnce weekly SC, 80 weeks3
TRIUMPH-2 (NCT05929079)Adults with obesity and type 2 diabetes; n=1,1524, 9, 12 mgOnce weekly SC, 80 weeks4
TRANSCEND-T2D-1 (NCT06354660)Adults with type 2 diabetes on diet and exercise; n=5374, 9, 12 mgOnce weekly SC, 40 weeks5
Figure 1. Dose levels named in ClinicalTrials.gov arm descriptions that mention Retatrutide, counted once per study (3 interventional studies). Includes titration steps and single-dose pharmacology studies; a level appearing often is not evidence that it is effective or safe.

Arms as registered

Verbatim arm text from ClinicalTrials.gov. Only arms naming Retatrutide and a dose are shown.

  1. NCT07467447 · Phase 2 · Recruiting · n=300

    Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

    • Retatrutide (LY3437943) 1 mg once weekly (no escalation)
    • Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.
    • Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).
    • Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg
    • Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.
    • Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.

  2. NCT04881760 · Phase 2 · Completed · n=338

    A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

    • 1 milligram (mg) LY3437943 — Participants received 1 mg LY3437943 administered as SC injection QW.
    • 4 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
    • 4 mg LY3437943 — Participants received 4 mg LY3437943 administered as SC injection QW.
    • 8 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
    • 8 mg LY3437943 (4 mg) — Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
    • 12 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

  3. NCT04867785 · Phase 2 · Completed · n=281

    A Study of LY3437943 in Participants With Type 2 Diabetes

    • 0.5 milligrams (mg) LY3437943 — Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
    • 4 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
    • 4 mg LY3437943 (4 mg) — Participants received 4 mg LY3437943 administered as SC injection QW.
    • 8 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
    • 8 mg LY3437943 (4 mg) — Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
    • 12 mg LY3437943 (2 mg) — Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.

References

Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.

  1. 1 PubMed Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023. PMID 37366315; doi:10.1056/NEJMoa2301972.
  2. 2 PubMed Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023. PMID 37385280; doi:10.1016/S0140-6736(23)01053-X.
  3. 3 PubMed Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026. PMID 42814954; doi:10.1056/NEJMoa2604169.
  4. 4 PubMed Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet 2026. PMID 42810372; doi:10.1016/S0140-6736(26)01861-1.
  5. 5 PubMed Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 2026. PMID 42250575; doi:10.1016/S0140-6736(26)00967-0.

← Retatrutide monograph · Why we publish trial doses